Polyglot Systems, CarePoint partner to help healthcare providers communicate medication instructions
MORRISVILLE, N.C. — Polyglot Systems and CarePoint have partnered to help healthcare providers communicate medication instructions more effectively to patients, the two companies said Thursday.
CarePoint has integrated Polyglot’s Meducation product with its GuardianRx Total Pharmacy & Patient Management System, which will enable GuardianRx users to take advantage of such abilities as generating medication instructions in simplified and easy-to-understand formats in English and 11 other languages. Meducation communicates medication instructions using pictures, which comes in handy for patients who have trouble understanding English or reading.
“The increasingly diverse demographics of the country highlight the need for making medication instructions easily understandable, both for non-English-speaking patients and patients that struggle at higher reading levels,” CarePoint president and CEO Jim Whitney said. “The integration of Polyglot’s comprehensive product with our pharmacy management systems allows customers to more easily meet expanding government requirements while increasing the overall level of patient safety.”
According to the companies, evidence suggests that ineffective medication instructions contribute to diminished health outcomes and higher costs.
“Medication mistakes are the most common form of medical errors in this country, resulting in more than 700,000 emergency room visits and nearly 120,000 hospitalizations,” Polyglot founder and president Charles Lee said. “A recent study has shown that improving medication adherence could save up to $7,800 per patient each year. We are thrilled to partner with a company of CarePoint’s vision [that] recognizes this critical need.”
FDA approves Dr. Reddy’s generic anticoagulant drug
HYDERABAD, India — The Food and Drug Administration has approved a generic anticoagulant drug made by Dr. Reddy’s Labs and Alchemia.
Dr. Reddy’s and Brisbane, Australia-based Alchemia announced the FDA approval of fondaparinux sodium injection in the 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL and 10 mg/0.8 mL strengths. Alchemia owns the patents covering the process for synthesis of fondaparinux.
The drug is a generic version of GlaxoSmithKline’s Arixtra. Arixtra had sales of about $340 million during the 12-month period ended in May, according to IMS Health.
Teva completes acquisition of Japanese generics company
JERUSALEM — Teva Pharmaceutical Industries has completed its acquisition of Japan’s third-largest generics company, Teva said.
The Israeli drug maker, the world’s largest maker of generic drugs, announced that it had acquired effectively all the outstanding shares of Taiyo Pharmaceutical Industry Co. for $934 million.
“This is an important milestone in executing Teva’s long-term strategic plan,” Teva president and CEO Shlomo Yanai said in a statement. “The acquisitio of Taiyo, along with Teva’s existing Japanese business, assures that Teva will deliver on our strategic objective of becoming a leading player in Japan.”
Taiyo had sales of about $530 million in 2010, and its acquisition adds more than 550 products to Teva’s portfolio, as well as Taiyo’s research and development team, local regulatory expertise and a factory. Teva said it expected its sales in Japan to reach $1 billion after the purchase.